SFBN Trending: Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 https://zpr.io/YrcBKGmidbcG
bionetworks Trending: Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study https://zpr.io/9tPLKpLKRxMf
SDBN Trending: Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 https://zpr.io/NMitCtmVCrMb
SDBN Trending: Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture https://zpr.io/ZUWD7WCSNrr5
bionetworks Trending: BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics https://zpr.io/CbUNv6ZhjjKK
bionetworks Trending: Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC https://zpr.io/fEDPJD5XQxAn
